Business
Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® (edaravone) and IV RADICAVA
OSAKA, Japan, December 22, 2025--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that its Board of Directors, at a meeting held on December 22, 2025, resolved to acquire a newly established company that Tanabe Pharma Corporation (Head Office: Osaka, Japan; Chief Executive Officer: Akihisa Harada; hereafter "Tanabe Pharma") will create to hold the rights to RADICAVA ORS® (edaravone) and IV RADICAVA. Tanabe Pharma pla
About this update from Shionogi & Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":385,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/8767212fe2e0340318d7e577156c6303"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4AS8ZVc0YijodNIUqh2dnA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTg3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8767212fe2e0340318d7e577156c6303","width":385,"height":480}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Shionogi to purchase the rights and assets of the global RADICAVA business establishing a strong commercial platform in rare disease to support future launches","length":159,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"As part of the transaction, a new business company established by Tanabe for RADICAVA in the U.S. will become a wholly owned subsidiary of Shionogi Inc.","length":152,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Transaction expected to be immediately accretive in FY26, adding approximately USD 700 million in annual global sales","length":117,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":428,"olType":false},{"type":"text","content":"OSAKA, Japan, December 22, 2025--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that its Board of Directors, at a meeting held on December 22, 2025, resolved to acquire a newly established company that Tanabe Pharma Corporation (Head Office: Osaka, Japan; Chief Executive Officer: Akihisa Harada; hereafter "Tanabe Pharma") will create to hold the rights to RADICAVA ORS® (edaravone) and IV RADICAVA. Tanabe Pharma plans to form this new entity, and Shionogi intends to purchase 100% of its shares. The agreement between Shionogi and Tanabe Pharma was signed this afternoon. As part of the transaction, a new business company established by Tanabe for RADICAVA in the U.S. will become a wholly owned subsidiary of Shionogi Inc.","length":850,"tagName":"p"},{"type":"text","content":"RADICAVA ORS is approved by the U.S. Food and Drug Administration (FDA) and other regulatory agencies around the world for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenera...